For Healthcare Professionals

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

clipboard-pencil

About the study

The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Participants with liver biopsy fibrosis score stage 4 (NASH CRN) performed within 12 months
  2. Men and women must agree to follow methods of contraception

EXCLUSION CRITERIA

  1. Worsening liver disease or any disease might compromise participant safety in the opinion of the investigator
  2. Known immunocompromised status or any disease or condition which might compromise participant safety
  3. Prior exposure to BMS-986263
  4. Clinically relevant abnormal physical examination, vital signs, ECG, or clinical laboratory tests
  5. Hepatic decompensation Other protocol-defined inclusion/exclusion criteria apply
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 855-907-3286Email iconEmail Study Center

Study’s details


Contition

Nonalcoholic Steatohepatitis (NASH)

Age (in years)

21 - 75

Phase

Phase 2

Participants needed

270

Est. Completion Date

Dec 2026

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT04267393

Study number

IM025017

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.